Background: The trend in the incidence of hospitalized acute myocardial infarction (AMI) and the difference between regions has not been reported in Korea since 2010. Thus, we aimed to inspect recent trends and regional differences in the incidence of AMI and case-fatality between 2007 and 2016.

Methods: Data from the medical utilization cohort from 2002 to 2016 were analyzed. New incidence of AMI was identified by checking the diagnosis code, duration of admission, type of test, treatment, and medication. Age-standardized incidence rate by gender, age group, and resident region was calculated from 2007 to 2016. Cumulative case-fatality rate was calculated until 3 years.

Results: Age-standardized incidence of hospitalized AMI decreased from 53.6 cases per 100,000 person-years in 2007 to 38.9 cases in 2011. Thereafter, the incidence gradually increased to 43.2 cases in 2016. The trend by gender and age groups was also similar to the total trend. The regional age-standardized incidence was the highest in Daegu (50.3 cases per 100,000 person-years) and the lowest in Sejong (30.2 cases), which were similar to the ischemic heart disease mortality in these regions. The 7-, 30-, and 90-days and 1- and 3-years average case-fatality over 10 years were 3.2%, 6.9%, 9.9%, 14.7%, and 22.4%, respectively.

Conclusion: Although case-fatality continuously decreased from 2007 to 2016, hospitalized AMI incidence decreased from 2007 to 2011 and gradually increased from 2011 to 2016, with marked disparity between regions. Effective preventive strategies to decrease AMI incidence are required to decrease cardiovascular disease mortality in Korea.

Keywords: Acute Myocardial Infarction; Incidence Rate; Case-Fatality; Regional Differences
Funding
This research was supported by Gyeongsang Hospital Regional Cardiocerebrovascular Disease Center through the operating expenses funded by the Ministry of Health and Welfare Ministry of Korea (2018).

Disclosure
The authors have no potential conflicts of interest to disclose.

Author Contributions
Conceptualization: Hwang JY, Kim RB. Data curation: Kim RB, Kim HS, Kang DR. Formal analysis: Kim RB, Kim HS. Investigation: Kim RB, Choi JY. Methodology: Kim RB, Kang DR. Software: Kim RB, Kim HS. Validation: Kang DR, Choi JY. Writing - original draft: Kim RB, Kim HS. Writing - review & editing: Hwang JY, Hwang S, Choi NC.

INTRODUCTION
Cardiovascular diseases (CVDs) are the leading cause of death (about 30% of deaths) worldwide. In Korea, CVDs carry the second highest death rate following cancer, and the recent trend is increasing. Most countries have surveillance systems and annually investigate current death statistics owing to its importance. However, data on the incidence of CVDs other than that from mortality rates are lacking because it is more difficult to detect incidence of CVDs than to assess the death rate due to CVD among the total population, and the cost for investigation is also high.

Many countries, including the Asian countries, have reported on recent trends (since 2010) in the incidence rate of CVDs. However, there has been little research on the incidence of CVDs in Korea since 2010. Therefore, there is a lack of accurate data on the recently increased CVD mortality in Korea and limitations in establishing and evaluating policy strategies for CVDs.

In Korea, the entire population is covered by the National Health Insurance Service (NHIS), which manages all medical utilization and claims data. Recently, the NHIS disclosed medical insurance claims data of the Korean population for research purposes, which can help identify the disease name, type of examination, and treatment, as well as the medical institution where treatment was obtained. Therefore, these data can be used to confirm the incidence of CVDs, especially acute myocardial infarction (AMI). Furthermore, as data from the year 2002 have been released, the trend in the long-term AMI incidence can be evaluated.

In this study, using medical insurance claims data, we investigated the 10-year trend between 2007 and 2016 in the incidence of AMI in patients who received in-hospital treatment and analyzed the regional AMI incidence to explain the regional AMI mortality disparity. Additionally, the AMI case-fatality after hospitalization was determined.

METHODS
Data sources
Data used were from the NHIS claims data. This data is a cohort from 2002 of the medical utilization of all Koreans, which is about 50 million. Data include information such as the type of medical institutions, date of visit, duration of admission, International Classification of Diseases (ICD)-10 code for treated diseases, and type of treatment including procedures and medications. Socio-demographic information such as gender, age, and residence province are also included. In case of death of the insured, the date and cause of death are included by using linked Statistical Office mortality data. The NHIS data usage procedures are shown in Supplementary Table 1.

In this analysis, we used 15 years of medical utilization data from 01 January 2002 to 31 December 2016. Data from 2002 to 2006 (5 years) were used as a washout period to define newly diagnosed patients and to exclude these patients in subsequent years for identification of new cases from 2007 to 2016.

Identification of newly diagnosed AMI
In the NHIS claims data, there are no records of symptoms, electrocardiogram (ECG) findings, or results of cardiac biomarker tests. Therefore, we identified patients with newly diagnosed AMI based on the following steps.
First, for the period from 2007 to 2016, patients diagnosed with AMI (ICD-10 code: I21.0–I21.9) in the main diagnosis code or in the four sub-diagnosis codes were identified by each year. Second, among the identified patients, those diagnosed with AMI between 2002 and the previous year of the year diagnosed were excluded from the incidence cases. For example, a 2007 incidence patient was never diagnosed between 2002 and 2006, and incident patients at 2013 were never diagnosed between 2002 and 2012. In addition, patients with 1-day duration of admission were excluded. Third, among patients who met the first and second conditions, those who fulfilled two or more of the following three conditions were analyzed for the incidence of AMI: 1) Patients who underwent a MB fraction of creatine kinase or troponin tests at admission; 2) those who underwent a coronary artery angiography or percutaneous coronary intervention (PCI) or thrombolysis or coronary artery bypass grafting (CABG); and 3) those prescribed antiplatelet agents such as aspirin or clopidogrel.

In the NHIS claims data, all tests, procedures, treatments, and drugs are coded. Therefore, the corresponding code was checked and retrieved to extract the patient data, and the detailed code has been summarized in Supplementary Tables 2 and 3.

Analysis of outcomes

From 2007 to 2016, the crude incidence rate was calculated by dividing the number of patients in each year by the mid-year population. Also, we calculated the incidence rate by gender, age groups (0–29, 30–39, 40–49, 50–59, 60–69, 70–79, and over 80 years), and 17 regions (8 metropolitan cities and 9 provinces) of Korea based on the patient residence. The age standardization incidence rate was calculated to compensate for the difference in the proportion of the population between the age groups by year. At this juncture, we set the standard population to the mid-year population in 2011, and the calculation formula used was as follows.

Age-standardized incidence rate (per 100,000 person-years) for each year = \( \sum \) (incidence rate by age groups at each year × number of standard population by age groups) × 100,000/total number of standard population.

To summarize the incidence over the entire period and to compare the incidence rates between the 17 regions easily, we calculated the average incidence rate (per 100,000 person-years) during the study period by the following formula.

Average age-standardized incidence rate (per 100,000 person-years) during 10 years = \( \sum \) (incidence rate by age groups during 10 years × number of standard population by age groups) × 100,000/total number of standard population.

In the case of the Sejong province which is a new administrative region in 2012, we calculated the average age-standardized incidence rate during four-years.

We calculated the 7-days, 30-days, 90-days, 1-year, and 3-years all-cause case-fatality (%) from the date of admission for AMI by dividing the cumulated number of deaths for each period by the total number of AMI patients for each year. The 3-years case-fatality of 2014, 2015, and 2016, and the 1-year case-fatality of 2016 were not calculated to avoid misleading values due to underestimation.

We used SAS version 9.4 (SAS Institute, Cary, NC, USA) for all analyses, and we did not use any statistical testing method because data of the entire population was used instead.
of a sample data. The figures in this study were plotted by using R software version 3.5.2 (R Foundation for Statistical Computing, Vienna, Austria) with package ‘ggplot2.’ The map geometric shape file was downloaded from the website of GIS developer (http://www.gisdeveloper.co.kr/?p=2332).

Ethics statement
This study was an analysis of secondary data from the NHIS. The data set did not include any personal information such as patient name, social security number, address, or phone number. Only non-identifiable aggregate results that were openly available for public research purposes were released and informed consent could not be obtained. The present study protocol was reviewed and approved by the Institutional Review Board of Gyeongsang National University Hospital (approval No. GNUH 2018-05-017).

RESULTS
Incidence rate of hospitalized AMI
We identified 214,646 patients who were newly hospitalized with AMI enrolled from the Korean NHIS data for the period between 2007 and 2016. Of the total patients, 67.8% were men, and the proportion of men patients was seen to steadily increase from 62.4% (2007) to 70.5% (2016) (Table 1).

The age-standardized incidence rate of hospitalized AMI decreased from 53.6 cases per 100,000 person-years in 2007 to a lowest of 38.9 cases per 100,000 person-years in 2011 (relative decrease between 2007 and 2011, 27.4%). Following this, the age-standardized incidence increased steadily to 43.2 in 2016 (relative increase between 2011 and 2016, 11.1%)

Table 1. Annual incident cases and incidence rate of hospitalized acute myocardial infarction

| Variables                      | 2007   | 2008   | 2009   | 2010   | 2011   | 2012   | 2013   | 2014   | 2015   | 2016   | Total over 10 years |
|--------------------------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------------------|
| Incident cases, Total, No      | 22,261 | 20,364 | 19,978 | 19,412 | 19,149 | 20,255 | 21,306 | 22,750 | 23,640 | 25,531 | 214,646           |
| Men, %                         | 62.4   | 64.2   | 65.1   | 67.1   | 68.1   | 68.9   | 69.9   | 70.0   | 70.7   | 70.5   | 67.8              |
| Age group, yr, %               |        |        |        |        |        |        |        |        |        |        |                   |
| 0–29                           | 0.4    | 0.2    | 0.4    | 0.3    | 0.3    | 0.2    | 0.2    | 0.2    | 0.2    | 0.2    | 0.3              |
| 30–39                          | 2.7    | 2.6    | 2.4    | 2.5    | 2.2    | 2.1    | 2.4    | 2.1    | 2.0    | 2.0    | 2.3              |
| 40–49                          | 10.9   | 11.1   | 11.1   | 10.8   | 10.7   | 10.8   | 11.2   | 10.9   | 10.3   | 10.0   | 10.8             |
| 50–59                          | 18.9   | 19.0   | 19.8   | 20.4   | 22.3   | 22.2   | 22.1   | 22.3   | 21.9   | 21.5   | 21.0             |
| 60–69                          | 24.8   | 24.2   | 23.0   | 23.5   | 22.2   | 22.4   | 22.2   | 22.3   | 23.5   | 23.7   | 23.2             |
| 70–79                          | 27.4   | 27.2   | 27.5   | 27.1   | 26.9   | 26.8   | 26.1   | 25.4   | 25.1   | 24.5   | 26.3             |
| ≥ 80                           | 14.1   | 15.3   | 15.4   | 15.1   | 15.2   | 15.2   | 15.6   | 16.5   | 17.9   | 17.9   | 15.8             |
| Incidence rate (per 100,000 persons-year) |    |        |        |        |        |        |        |        |        |        |                   |
| Total, crude rate              | 45.3   | 41.2   | 40.2   | 38.9   | 38.2   | 40.2   | 42.1   | 44.8   | 46.4   | 50.0   | 42.8*            |
| Total, age-standardized rate   | 53.6   | 47.0   | 44.1   | 41.1   | 38.9   | 39.5   | 40.0   | 41.2   | 41.4   | 43.2   | 41.7*            |
| Men, crude rate                | 56.4   | 52.8   | 52.3   | 52.2   | 52.0   | 55.4   | 58.9   | 62.8   | 65.6   | 70.5   | 57.9*            |
| Women, crude rate              | 33.6   | 29.2   | 27.8   | 25.3   | 24.2   | 24.9   | 25.2   | 26.7   | 27.0   | 29.3   | 27.3*            |
| Age group, yr, %               |        |        |        |        |        |        |        |        |        |        |                   |
| 0–29                           | 0.5    | 0.3    | 0.4    | 0.3    | 0.3    | 0.2    | 0.3    | 0.3    | 0.3    | 0.3    | 0.3*             |
| 30–39                          | 7.0    | 6.2    | 5.7    | 5.9    | 5.1    | 5.3    | 6.3    | 6.1    | 6.1    | 6.9    | 6.1*             |
| 40–49                          | 28.7   | 26.2   | 25.4   | 24.2   | 23.5   | 25.2   | 27.2   | 28.2   | 27.6   | 29.3   | 26.5*            |
| 50–59                          | 73.7   | 64.4   | 62.6   | 58.8   | 59.5   | 59.6   | 60.5   | 63.4   | 63.5   | 66.4   | 63.1*            |
| 60–69                          | 145.9  | 126.0  | 114.7  | 111.5  | 102.6  | 107.7  | 109.1  | 112.2  | 115.2  | 117.7  | 115.9*           |
| 70–79                          | 284.5  | 243.9  | 228.6  | 207.0  | 192.5  | 191.0  | 185.5  | 187.6  | 189.6  | 197.4  | 207.3*           |
| ≥ 80                           | 429.3  | 385.8  | 363.5  | 322.3  | 299.8  | 296.1  | 297.2  | 311.5  | 303.0  | 321.3  | 327.5*           |

*Average incidence rate per 100,000 person-years during 10 years.
(Table 1 and Fig. 1). This trend of AMI incidence which showed a decrease until 2011 and then increased till 2016 was similar in both the genders and all age groups. The age group with the highest incidence was 80+ years during the whole period (Table 1).

We found a marked difference in the average age-standardized incidence rate of hospitalized AMI over 10 years among the 17 administrative regions in Korea (Fig. 2). Daegu, Jeju, and Gwangju Province showed the highest average AMI incidence rates of 50.3, 47.3, and 47.1 per 100,000 person-years, respectively. On the other hand, Sejong, Chungnam, and Incheon Province showed low average incidence rates of 30.2, 37.9, and 38.4 per 100,000 person-years, respectively. The highest incidence rate of Daegu city was relatively 66.6% higher than that of the lowest Sejong city. The annual age-standardized incidence rates of the 17 regions from 2007 to 2016 are shown in Supplementary Table 4.

**Case-fatality of AMI patients**

Over 10 years, the 7-days, 30-days, 90-days, 1-year, and 3-years cumulated average case-fatality of all the hospitalized AMI patients was 3.2%, 6.9%, 9.9%, 14.7%, and 22.4%, respectively.

![Fig. 1. Trend in incidence rate of hospitalized acute myocardial infarction between 2007 and 2016.](https://jkms.org)
In 2007, the 7-days, 30-days, 90-days, 1-year, and 3-years cumulated case-fatality of all the hospitalized AMI patients was 3.5%, 8.0%, 11.6%, 17.3%, and 25.0%, respectively. Since then, the all-period cumulated case-fatality has decreased gradually, and in 2016 the case-fatality was 2.8%, 6.2%, 8.8%, 13.1% (in 2015), and 19.7% (in 2013), respectively (Fig. 3).

The all-period case-fatality of women was relatively higher by about 72% to 92% than that of men (Table 2). However, the decreasing trend of case-fatality from 2007 to 2016 was similar (Fig. 3). In 2007, the 7-days, 30-days, 90-days, 1-year, and 3-years cumulated case-fatality of all the hospitalized AMI patients was 3.5%, 8.0%, 11.6%, 17.3%, and 25.0%, respectively. Since then, the all-period cumulated case-fatality has decreased gradually, and in 2016 the case-fatality was 2.8%, 6.2%, 8.8%, 13.1% (in 2015), and 19.7% (in 2013), respectively (Fig. 3). The all-period case-fatality of women was relatively higher by about 72% to 92% than that of men (Table 2). However, the decreasing trend of case-fatality from 2007 to 2016 was similar.
in both the genders (Table 2). The annual case-fatality by age groups has been shown in Supplementary Table 5.

**DISCUSSION**

Although mortality and case-fatality of AMI has been reported from several registries and monitoring data, this study is the first to report on the incidence of hospitalized AMI in Korea using the entire population medical utilization cohort data from 2007 to 2016. The average total annual incidence was 21,465 cases. The average crude incidence rate during the whole period was 42.8 per 100,000 person-years (men 57.9 and women 27.3). The age-standardized incidence rate for AMI showed a decreasing trend from 2007 to 2011 and a slightly increasing trend from 2011 to 2016. However, all-period case-fatality in hospitalized AMI patients showed a decreasing trend between 2007 and 2016. We also found that the region with high age-standardized mortality due to ischemic heart disease was highly associated with the region with high age-standardized AMI incidence in Korea.

Although the pattern of decrease and increase in the incidence rate of AMI over the last 10 years may reflect the actual AMI incidence, careful consideration should be exercised in interpreting these data.

First, the diagnosis of AMI diagnosis was influenced to a large extent by the sensitivity of cardiac markers such as troponin I and T. Following the development of radioimmunoassays to detect serum troponin in the 1990s,11 cardiac troponin (cTn) assays have been used to diagnose myocardial infarction. However, since 2010, highly sensitive cTn (hs-cTn) assays have been developed and widely used.12,13 In fact, among patients with suspected AMI, those tested by the hs-cTn assay were diagnosed to have AMI more often (22% higher) than those tested by the cTn assay.14 Particularly, the hs-cTn assay had a higher sensitivity than that of the cTn assay and contributed to the increasing diagnostic rate of type I AMI and to the decreasing diagnostic rate of unstable angina.14 In addition, the development of rapid diagnostic kits in the middle of the decade 2001–2010 helped in a quick diagnosis in the emergency room rather than in the laboratory15,16 and may have contributed to the increase in the incidence rate of AMI.

Second, the definition and the diagnostic criteria of AMI have been changed in the 1950s.17 Thus, the incidence of AMI may be affected by the changed diagnostic criteria. The main
points of change in the diagnostic criteria of AMI occurred in 2000, 2007, and 2012. In 2000, the task force of the European Society of Cardiology and the American College of Cardiology changed the definition of AMI using a biochemical and clinical approach that demanded an elevation of cardiac biomarkers before myocardial infarction could be diagnosed rather than the traditional epidemiological approach. After the new definition of AMI was introduced, the numbers of AMI patients increased. In 2007, the same task force redefined AMI, with less emphasis on ECG and symptoms and more meaningful implications for cTn than that in the 2000 definition. They also introduced the new AMI diagnostic classification system with five subcategories. According to the study which analyzed the incidence difference between the diagnostic criteria in the same patient data, the incidence based on the 2007 criteria was about 11% lower than that based on the 2000 criteria. Therefore, it can be explained to some extent that the incidence rate has been continuously decreasing from 2007 as seen in our results. In 2012, a third definition for AMI was published. The most prominent changes in the third definition cover the distinction between myocardial ischemia and myocardial injury (or cardiac others) and the third criteria define AMI in the setting of cardiac interventions such as PCI and CABG. Because of this change, the patients who were actually diagnosed to have other cardiac conditions such as myocarditis, Takotsubo cardiomyopathy, or tachyarrhythmias were classified as type 2 AMI according to the 2012 definition, which resulted in a 6% incidence increase than that by the 2007 definition.

Therefore, it can be inferred that the improvement in the analytic performance of troponin assays and the change of definition for AMI are among the causes for the trend seen in the incidence rate. Our inference is convincing because recent trends in the incidence of AMI in other countries tend to be similar to that seen in this study. Some studies have shown a large decrease in the incidence rate before 2010 or 2011; however, thereafter the incidence rate has shown a relatively small decrease or has remained steady. Studies from Singapore, Poland, and Japan have reported a slight increase in the rates again from 2011, like in this study. Despite the effect of introduction of hs-cTn and the new definition of AMI, Korean health providers should change the preventive strategies to decrease the incidence of AMI as it has remained steady since 2011.

Statistics Korea death data showed marked disparity in CVD mortality by regions in Korea, with the south-eastern areas of Korea such as Daegu, Gyeongbuk, Gyeongnam, and Busan showing a remarkably high mortality for CVD. We first found the disparity in the average age-standardized incidence rates (lowest 30.2 to highest 50.3 per 100,000 person-years) between regions. On comparing these results with the Statistics Korea death data, in general except on Jeju, the regions of high AMI incidence tended to have higher ischemic heart disease mortality and the regions of low AMI incidence tended to have lower ischemic heart disease mortality. In Jeju, the reason for the low ischemic heart disease mortality compared to the high AMI incidence cannot be known exactly. However, based on Statistics Korea data (http://kosis.kr/index/index.do), we assume that generally in Jeju compared to other regions, the higher public ambulance utilization and faster emergency room visits after AMI symptoms may be the reason.

These results suggest that the high mortality rates in the region are not a consequence of the regional hospital care system, but of the incidence of the disease per se. Therefore, it is necessary to first prevent the incidence of myocardial infarction in order to reduce the mortality rate.
The trend for all-period case-fatality in hospitalized AMI patients showed a decrease from 2007 to 2016. This declining trend was the same shown in other recent studies. This decrease can be explained by improvements in healthcare facilities and therapeutic technologies such as medical devices and medicines. Additionally, since 2011, the cardiovascular intervention institute/specialist certification system has been implemented to provide prompt and appropriate treatment for AMI patients in Korea. As a result, the proportion of initial PCI procedures has increased steadily (99.1% in 2018) till recent years, and the door-to-balloon time has been relatively reduced, about 60 minutes. Moreover, because the government has promoted awareness and education about the early symptoms of AMI from the late 2000s, the symptoms-to-door time has also shown a gradual decrease. The proportion of ST-elevation myocardial infarction (STEMI) patients is markedly continuing to decrease compared to that of non-STEMI (NSTEMI) patients. These factors may contribute to the decrease in the case-fatality of hospitalized AMI patients over 10 years. The case-fatality was much lower in men than in women, because women patients were older than the men patients, and the higher the age, the higher the case-fatality in patients.

This study has several limitations as we have used NHIS data which include medical utilization cohort data for 15 years. The insurance claims data do not have information on symptoms, ECG records, and laboratory results, and the diagnostic accuracy is also low. In a study comparing hospital clinical data with NHIS data, the diagnostic accuracy for all diseases was 69.7%. However, the diagnosis of an acute phase disease such as AMI is more accurate. We believe that the diagnostic accuracy was not a significant limitation in our study, because we considered the duration of admission, type of diagnostic test, procedures for treatment, and the use of antiplatelet drugs besides the AMI diagnostic code. Second, there is the limitation that the incidence of AMI at a population level may be underestimated because AMI cases who did not visit hospitals and died directly on the site are not included in the NHIS data. Also, the incidence and case-fatality may be underestimated because those who died within a day after arriving at the emergency room were excluded. However, this study focused on the incidence of hospitalized AMI, and not on the total population incidence of AMI. In addition, when calculating the AMI incidence rate in NHIS data, the results may vary under different conditions. That is, depending on how a combination of conditions, such as diagnosis code, laboratory code, procedure code, and medication code, the result may vary. Therefore, when interpreting this study, it is necessary to focus on the 10-years trend rather than on the absolute values of AMI incidence. Third, in this study, differences in incidence rates by region were calculated. Among the causes of regional differences, there may be a difference in incidence due to differences in diagnostic criteria of medical doctors in different regions. However, in this study, the analysis was made on the assumption that the diagnostic criteria of medical doctors in Korea are similar. Finally, we did not analyze the AMI by subgroups into STEMI and NSTEMI, and did not separate all-cause fatality and cardiovascular fatality. Because it was difficult to distinguish the type of AMI and cause of death from the NHIS claims data. Therefore, it is necessary to pay attention to the interpretation of data results, and it is necessary for further research to separate the types of AMI and the causes of death.

Despite these limitations, the strength of this study was confirmation of the relatively long-term trends in the AMI incidence rate for the entire population of Korea. Another strong point of this study was the analysis of the difference in the AMI incidence rate by regions to reveal the causes for the difference in AMI mortality in Korea. In addition, it is meaningful that this study analyzed not only the 7-days and 30-days case-fatality of AMI, but also the case-fatality for the extended period of 90 days, 1 year, and 3 years.
In conclusion, the incidence rate of hospitalized AMI in Korea decreased from 2007 to 2011 and then tended to increase gradually until 2016. Moreover, there was a difference in the incidence rate of AMI between the 17 regions of Korea. Finally, the all-period case-fatality of AMI patients has shown a steady decrease from 2007 to 2016.

**SUPPLEMENTARY MATERIALS**

**Supplementary Table 1**  
NHIS claim data usage process  
Click here to view

**Supplementary Table 2**  
Codes on National Health Insurance Service data set for checking AMI patients  
Click here to view

**Supplementary Table 3**  
Codes on National Health Insurance Service data set for checking acute myocardial infarction patients  
Click here to view

**Supplementary Table 4**  
Annual age-standardized incidence rate of hospitalized acute myocardial infarction by 17 regions in South Korea  
Click here to view

**Supplementary Table 5**  
Annual case-fatality after diagnosis of acute myocardial infarction by age groups  
Click here to view

**Supplementary Table 6**  
Age-standardized ischemic heart disease mortality, proportions for utilization of public ambulance and arrival at emergency room within 60 minutes in AMI patients  
Click here to view

**Supplementary Fig. 1**  
Correlation relationship between AMI incidence rate and ischemic heart disease mortality during 2007 to 2016. The IHD mortality is based on KOSIS data from the Statistic Korea. The AMI incidence is the result of this study.  
Click here to view
REFERENCES

1. World Health Organization. The top 10 causes of death. https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Updated 2018. Accessed June 21, 2019.

2. Korea National Statistical Office. 2017 The annual report on the cause of death statistics. http://kostat.go.kr/portal/korea/kor_nw/1/index.board?bmode=read&bSeq=saSeq=370710&pageNo=1&rowNum=10&navCount=10&searchWord=src&k=Target=title&kText=EC%82%AC%EB%A7%9D%EC%9B%90%EC%9D%B8. Updated 2018. Accessed June 21, 2019.

3. Bhatnagar P, Wickramasinghe K, Wilkins E, Townsend N. Trends in the epidemiology of cardiovascular disease in the UK. Heart 2016;102(24):1945-52.

4. Read SH, Fischbacher CM, Colhoun HM, Gasevic D, Kerssens JJ, McAllister DA, et al. Trends in incidence and case fatality of acute myocardial infarction, angina and coronary revascularisation in people with and without type 2 diabetes in Scotland between 2006 and 2015. Diabetologia 2019;62(3):418-25.

5. Sulo G, Iglund J, Vollset SE, Ebbing M, Egeland GM, Ariansen I, et al. Trends in incident acute myocardial infarction in Norway: an updated analysis to 2014 using national data from the CVDNOR project. Eur J Prev Cardiol 2018;25(10):1031-9.

6. National Registry of Diseases Office. Singapore myocardial infarction registry annual report 2016. https://www.nrdo.gov.sg/docs/librariesprovider3/default-document-library/smir-web-report-2016.pdf?sfvrsn=0. Updated 2018. Accessed June 21, 2019.

7. Plakht Y, Gilutz H, Shiyovich A. Temporal trends in acute myocardial infarction: What about survival of hospital survivors? Disparities between STEMI & NSTEMI remain. Soroka acute myocardial infarction II (SAMI-II) project. Int J Cardiol 2016;203:1073-81.

8. Yamamoto T, Yoshida N, Takayama M; Tokyo CCU Network. Temporal trends in acute myocardial infarction incidence and mortality between 2006 and 2016 in Tokyo - report from the Tokyo CCU network. Clin J 2019;83(6):1405-9.

9. Zhang Q, Zhao D, Xie W, Xie X, Guo M, Wang M, et al. Recent trends in hospitalization for acute myocardial infarction in Beijing: increasing overall burden and a transition from ST-segment elevation to non-ST-segment elevation myocardial infarction in a population-based study. Medicine (Baltimore) 2016;95(5):e2677.

10. Kim RB, Kim BG, Kim YM, Seo JW, Lim YS, Kim HS, et al. Trends in the incidence of hospitalized acute myocardial infarction and stroke in Korea, 2006–2010. J Korean Med Sci 2013;28(1):16-24.

11. Katus HA, Remppis A, Looser S, Hallemeier K, Scheffold T, Kübler W. Enzyme linked immuno assay of cardiac troponin T for the detection of acute myocardial infarction in patients. J Mol Cell Cardiol 1989;21(12):1349-53.

12. Garg P, Morris P, Fazlanie AL, Vijayan S, Dancso B, Dastidar AG, et al. Cardiac biomarkers of acute coronary syndrome: from history to high-sensitivity cardiac troponin. Intern Emerg Med 2017;12(2):147-55.

13. Gaze DC. Rapid cardiovascular diagnostics. In: Saxena SK, editor. Proof and Concepts in Rapid Diagnostic Tests and Technologies. London: IntechOpen; 2016, 17-32.

14. Reichlin T, Twerenbold R, Reiter M, Steuer S, Bassetti T, Balmelli C, et al. Introduction of high-sensitivity troponin assays: impact on myocardial infarction incidence and prognosis. Am J Med 2012;125(12):1205-1213.e1.

15. van de Kerkhof D, Peters B, Scharnhorst V. Performance of the Advia Centaur second-generation troponin assay TnI-ultra compared with the first-generation cTnI assay. Ann Clin Biochem 2008;45(Pt 3):316-7.

16. Scharnhorst V, Krasznai K, van’t Veer M, Michels R. Rapid detection of myocardial infarction with a sensitive troponin test. Am J Clin Pathol 2011;135(3):424-8.

https://jkms.org
https://doi.org/10.3346/jkms.2019.34.e322
17. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Rax JJ, Morrow DA, et al. Fourth universal definition of myocardial infarction (2018). *Eur Heart J* 2019;40(3):237-69.
18. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol* 2000;36(3):959-69.
19. Thygesen K, Searle J. Update on the universal definition of acute myocardial infarction in the light of new data. *Conf Pop Med* 2013;47:9352.
20. Thygesen K, Alpert JS, White HDJoint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. *Eur Heart J* 2007;28(20):2525-38.
21. Luepker RV, Duval S, Jacobs DR Jr, Smith LG, Berger AK. The effect of changing diagnostic algorithms on acute myocardial infarction rates. *Ann Epidemiol* 2011;21(11):824-9.
22. Thygesen K, Alpert JS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. *Nat Rev Cardiol* 2012;9(11):620-33.
23. Nestelberger T, Boeddinghaus J, Badertscher P, Twerenbold R, Wildi K, Breitenbücher D, et al. Effect of definition on incidence and prognosis of type 2 myocardial infarction. *J Am Coll Cardiol* 2017;70(13):1558-68.
24. Randall SM, Zilkens R, Duke JM, Boyd JH. Western Australia population trends in the incidence of acute myocardial infarction between 1993 and 2012. *Int J Cardiol* 2016;222:678-82.
25. Gierlotka M, Zdrojewski T, Wojtyniak B, Poloński L, Stokwiszewski J, Gasior M, et al. Incidence, treatment, in-hospital mortality and one-year outcomes of acute myocardial infarction in Poland in 2009–2012--nationwide AMI-PL database. *Kardiol Pol* 2015;73(3):142-58.
26. KOSIS (Statistics Korea). Age standardized mortality rate (1996–2017) by regions and cause of death. http://kosis.kr/statisticsList/statisticsListIndex.do?menuId=M_01_01&vwcd=MT_ZTITLE&parmTabId=M_01_01#SelectStatsBoxDiv. Updated 2019. Accessed June 21, 2019.
27. Dégano IR, Salomaa V, Veronesi G, Ferriéres J, Kirchberger I, Laks T, et al. Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations. *Heart* 2015;101(17):1413-21.
28. Nedkoff L, Knuiman M, Hung J, Briffa TG. Improving 30-day case fatality after incident myocardial infarction in people with diabetes between 1998 and 2010. *Heart* 2015;101(16):1318-24.
29. Kim Y, Ahn Y, Cho MC, Kim CJ, Kim YJ, Jeong MH. Current status of acute myocardial infarction in Korea. *Korean J Intern Med* 2019;34(1):110.
30. Park BJ, Sung JH, Park KD, Seo SW, Kim SW. Report of the Evaluation for Validity of Discharged Diagnosis in Korean Health Insurance Database. Seoul, Korea: Seoul National University; 2003.